Krafft et al., reported significantly higher levels of serum sPD-L1 among patients with high stage BC (T3–T4) compared to patients with low stage disease (T0–T2), although they found no association between sPD-L1 and lymphatic or visceral metastases [21]. This evidence concerns the gene SPDL1 and breast cancer.